Armer Jane M, Hulett Jennifer M, Bernas Michael, Ostby Pam, Stewart Bob R, Cormier Janice N
Sinclair School of Nursing Director, Nursing Research, Ellis Fischel Cancer Center Director, American Lymphedema Framework Project DC 116.05 Suite 415 EFCC University of Missouri-Columbia Columbia, MO 62011.
Sinclair School of Nursing University of Missouri-Columbia
Curr Breast Cancer Rep. 2013 Jun;5(2):134-144. doi: 10.1007/s12609-013-0105-0.
Breast cancer-related lymphedema (LE) is a progressive, chronic disease that affects millions of cancer survivors and primarily results from surgical lymphatic vessel/node removal and radiation therapy. Patient education and support for importance of early detection is essential in helping health care providers detect lymphedema early, when there is the best chance to prevent progression. Improved imaging and surgical techniques have decreased the incidence of LE; however, effective risk-reduction and treatment have historically lacked the level of evidence necessary to standardize effective treatment. The purpose of this article is to report an extensive review of literature, including highlighted multidisciplinary studies within the past three years, in order to update best practice guidelines in assessment, risk reduction, management, and surveillance for post-breast cancer lymphedema.
乳腺癌相关淋巴水肿(LE)是一种渐进性的慢性疾病,影响着数百万癌症幸存者,主要由手术切除淋巴管/淋巴结和放射治疗引起。对患者进行早期检测重要性的教育和支持,对于帮助医疗保健提供者在预防病情进展最佳时机时早期发现淋巴水肿至关重要。改进的成像和手术技术降低了LE的发病率;然而,有效的风险降低和治疗在历史上一直缺乏标准化有效治疗所需的证据水平。本文的目的是报告对文献的广泛综述,包括过去三年突出的多学科研究,以便更新乳腺癌后淋巴水肿评估、风险降低、管理和监测的最佳实践指南。